Dachaigh › Gnìomhan › General and Operations Managers › Cambridge, MA
General and Operations Managers ann an Cambridge, MA: Tuarastalan H-1B
41 iarrtasan cumhaichean-obrach airson an dreuchd seo le làrach-obrach ann an Cambridge, MA. Tuarastal bunasach meadhanach $172,500; leth meadhanach $140,000–$212,972.
A rèir ìre tuarastail
| Ìre tuarastail | Tuarastal meadhanach |
|---|---|
| Ìre I (innte) | $75,000 |
| Ìre II (càileachail) | $140,000 |
| Ìre III (eòlach) | $172,500 |
| Ìre IV (gu lèir comasach) | $274,000 |
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Luchd-fastaidh
| Neach-obrach | LCAs | Tuarastal meadhanach |
|---|---|---|
| Amgen Inc. | 3 | $140,000 |
| Massachusetts Institute of Technology | 3 | $400,000 |
| Circe Bioscience, Inc. | 2 | — |
| Vedanta Biosciences, Inc | 2 | $212,212 |
| Biogen Inc. | 2 | $219,720 |
| Everquote, Inc. | 2 | $132,020 |
| North Colony Asset Management, LLC | 2 | $170,000 |
| Microsoft Corporation | 2 | $175,000 |
| KoruLabs LLC | 2 | $71,000 |
| Mepsgenus Inc. | 2 | $138,000 |
| Sanofi US Services Inc. | 1 | $188,178 |
| ModernaTX, Inc. | 1 | $420,000 |
| Gelato USA LLC | 1 | $75,000 |
| Eli Lilly and Company | 1 | $294,170 |
| Integrity Lab Inc. | 1 | $175,000 |
| Ipsen Bioscience, Inc. | 1 | $215,250 |
| CIC Innovation Services, LLC | 1 | $170,000 |
| Ipsen Biopharmaceuticals, Inc. | 1 | $215,250 |
| Wecover Platforms Inc | 1 | $160,160 |
| Ankyra Therapeutics, Inc. | 1 | $274,000 |
| Iterative Scopes, Inc. | 1 | $160,000 |
| ARSA Sustainable Feedstocks LLC | 1 | $116,979 |
| Solvanic, Inc. | 1 | $115,000 |
| Start Hunt LLC | 1 | $70,700 |
| Synthpop Inc. | 1 | $165,000 |
| Prime Bubble Tea LLC | 1 | — |
| AgX Global, Inc | 1 | $90,000 |
| FortyFive Labs Incorporated | 1 | $163,301 |
| AirGarage, Inc | 1 | $190,000 |
Tiotalan dreuchd
- Operations Manager3
- Chief Executive Officer3
- Chief Operating Officer2
- Chief of Staff2
- Senior Director, Global Partnering2
- Business Development Manager2
- Business Management2
- President2
- Director of Strategy and Operations2
- Head, Portfolio Management & Operations1
- VP, Medical Affairs, Latent Viruses1
- Customer Insights Manager1
- Operations Manager 20516.3265.81
- Director, Strategy & Corporate Development (00053995)1
- Sr Director - Medical - Accelerated R&D Leadership Program1
Luchd-taic H-1B ann an Cambridge, MA →
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).